Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Expansion 2024-2033

Market Size –
The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market size has grown rapidly in recent years. It will grow from $4.55 billion in 2023 to $5.30 billion in 2024 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to the increasing number of ATMP clinical trials, rising awareness and belief among researchers regarding the benefits of advanced therapy, the presence of several ATMP CDMOs, increasing efforts to develop novel therapies for various diseases, and supportive government initiatives.

The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market size is expected to see rapid growth in the next few years. It will grow to $9.85 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to the high investment of CDMOs, a growing number of emerging players in the cell and gene therapy (CGT) sector, increasing grants and investments for the development of cell and gene therapies, increasing pharmaceutical R&D spending, increasing number of clinical trials for ATMPs. Major trends in the forecast period include advancements in AAV biomanufacturing facilities, expansion of cell and gene therapy manufacturing, technological advancements in cell and gene therapy, increasing need for access to advanced platforms and technologies, and incorporating advanced technologies such as CRISPR and next-generation sequencing for heightened accuracy.

Order your report now for swift delivery @
https://thebusinessresearchcompany.com/report/advanced-therapy-medicinal-products-contract-development-and-manufacturing-organization-cdmo-global-market-report

Scope Of Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Overview

Market Drivers –
The advanced therapy medicinal product contract development and manufacturing organization (CDMO) market size has grown rapidly in recent years. It will grow from $4.55 billion in 2023 to $5.30 billion in 2024 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to the increasing number of ATMP clinical trials, rising awareness and belief among researchers regarding the benefits of advanced therapy, the presence of several ATMP CDMOs, increasing efforts to develop novel therapies for various diseases, and supportive government initiatives.

Market Trends –
Major companies operating in the advanced therapy medicinal products CDMO market are developing advanced cell therapy manufacturing services to overcome critical issues in cell therapy manufacturing and speed the development activities of their partners. Cell therapy manufacturing services are contract development and manufacturing organization services that offer services which vary from early preclinical development to late-stage clinical trials and commercialization. For instance, in January 2024, Pluristem Therapeutics Inc., an Israel-based biotech company that transforms cells into solutions, launched PluriCDMO, a new business division offering cell therapy manufacturing. It utilizes a patented bioreactor system that allows for 3D cell multiplication, facilitating the production of a variety of cell types such as stem cells, induced pluripotent stem cells, exosomes, and immune therapies. PluriCDMO desires to provide high-quality, vital medicines to patients while maintaining unique batch-to-batch consistency in a scalable and cost-effective manner in good manufacturing practice settings.

The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market covered in this report is segmented –

1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology

Get an inside scoop of the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15719&type=smp

Regional Insights –
North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies –

Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market are Thermo Fisher Scientific Inc., Merck KGaA, Resonac Corporation, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions

Table of Contents
1. Executive Summary
2. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Characteristics
3. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Trends And Strategies
4. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market – Macro Economic Scenario
5. Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Size and Growth
.
.
.
31. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Other Major And Innovative Companies
32. Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Competitive Benchmarking
33. Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market
35. Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Future Outlook and Potential Analysis
36.Appendix